<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7101875/results/search/country/results.xml">
  <result pre="Abstract The coronavirus disease 19 (COVID-19) is quickly spreading across" exact="China" post="and globally. Pharmacy services are an important pillar in"/>
  <result pre="international pharmacy community in the response to these needs. Keywords" exact="China" post="Coronavirus COVID-19 Pharmaceutical care Pharmacists Pharmacy service Public health"/>
  <result pre="acute respiratory syndrome coronavirus (SARS-CoV-2) began in Wuhan, Hubei Province," exact="China" post="in December 2019 [1]. The genetic characteristics of SARS-CoV-2"/>
  <result pre="of March 12, 2020, there were 80,981 confirmed cases in" exact="China" post="(3173 deaths) and 44,067 cases in 117 countries/territories/areas outside"/>
  <result pre="China (3173 deaths) and 44,067 cases in 117 countries/territories/areas outside" exact="China" post="(1440 deaths) [3]. Currently there are no approved antiviral"/>
  <result pre="hospitals, the &quot;Square Cabin Hospitals&quot; have been built in Wuhan," exact="China" post="(the epidemic epicenter in China) to treat patients with"/>
  <result pre="Pharmacists are actively engaging in the public health operation in" exact="China" post="since the outbreak, either at their home hospitals and"/>
  <result pre="share our experiences of providing pharmacy services combating coronavirus in" exact="China" post="to disseminate what we have learned to the international"/>
  <result pre="pharmacyâ€™s responses in meeting the needs of pharmacy services in" exact="China" post="during the epidemic. Pharmacy responses to combat the coronavirus"/>
  <result pre="the epidemic. Pharmacy responses to combat the coronavirus epidemic in" exact="China" post="Response 1: Draft professional service guidance to pharmacists and"/>
  <result pre="specific vaccine and no effective antiviral therapy against SARS-CoV-2. The" exact="China" post="National Health Commission (CNHC) has released the &quot;Diagnosis and"/>
  <result pre="are based on past experiences during the SARS outbreak in" exact="China" post="in 2003 with the consideration of lack of drug"/>
  <result pre="activities Event-driven pharmaceutical care is provided to COVID-19 patients in" exact="China" post="during the epidemic. The event-driven pharmaceutical care goes beyond"/>
  <result pre="China) groups are established by pharmacy experts and pharmacists in" exact="China" post="to provide clinical support for front-line pharmacists in Hubei,"/>
  <result pre="through person-to-person transmission during the coronavirus epidemic, medical institutions across" exact="China" post="have launched remote pharmacy services such as online drug"/>
  <result pre="regarding the epidemic [13]. For example, after the media in" exact="China" post="reported that Shuanghuanglian, a TCM that contains extracts from"/>
  <result pre="for a coronavirus treatment. During the first week of February," exact="China" post="launched two placebo-controlled trials of remdesivir, slated to include"/>
  <result pre="high-quality evidence of treatment efficacy and safety. In response, the" exact="China" post="State Council issued the &quot;Notice on Standardizing Medical Institutions"/>
  <result pre="to the COVID-19 epidemic. The experiences and lessons learned in" exact="China" post="not only allow the Chinese pharmacy profession to improve"/>
 </snippets>
</snippetsTree>
